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Abstract 
Background: Adipose tissue functions as an endocrine organ by releasing 
adipokines which have important roles in the regulation of inflammation and 
insulin sensitivity. Although there is evidence of improvements in the 
circulating levels of adipokines with weight loss, few studies relate such 
changes to specific diets. We investigated the effect of weight loss achieved 
by two different diets on circulating adipokine levels in obese individuals.  
Methods: 120 obese patients (BMI ≥ 35 kg/m2) underwent a screening period 
of 3-months on a low fat, reduced-calorie diet.  Patients failing to achieve a 
5% weight loss using this approach were randomly allocated to either a low 
carbohydrate/high protein diet (LCHP) (n=17) or a commercial very-low-
calorie diet (LighterLife – LL) (n=14) for a period of 9-months. 
Results: A significant weight loss (Kg) only maintained for LL at 9-months (-
32.3 ± 22.7, p < 0.0001) but not LCHP. Changes in adiponectin (ng/ml) (15.8 
±  17.1 vs -0.8 ±  6.2, p = 0.003) and leptin (ng/ml) (-17.6 ±  24.3 vs -3.0 ±  
9.2, p = 0.049) at 9-months were significantly greater for LL than for LCHP 
which may reflect greater weight loss and decrease in fat mass. Changes in 
TNF-α, IL-6 and PAI-1 did not differ significantly between the dietary 
interventions at 9-months. 
Conclusions: A significant weight loss of 23.8% of baseline weight was 
observed using a very-low-calorie diet and resulted in significant 
improvements in circulating levels of leptin, PAI-1 and adiponectin, which are 
likely to be due to the weight loss and not the macronutrient intake. (ISRCTN: 
ISRCTN09760867) 
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Abbreviations: TNF, tumour necrosis factor; PAI-1, plasminogen activator 
inhibitor-1; IL-6, interleukin-6; RCT, randomised controlled trial; CDD, 600 
calorie deficient diet; LCHP, low carbohydrate high protein; VLCD, very-low- 
calorie diet; LL, LighterLife; HDL, high density lipoprotein cholesterol; HOMA-
IR, homeostasis model of assessment of insulin resistance; ELISA, enzyme-
linked immunoassay. 
 
Introduction 
It is now evident that adipose tissue not only stores excess triacylglycerols, 
but functions as an endocrine organ by releasing adipokines, which have 
important roles in the in the regulation of appetite, glucose and lipid 
metabolism, inflammation, and insulin resistance 1,2. Such adipokines include 
adiponectin, leptin, resistin, tumour necrosis factor (TNF)-α, plasminogen 
activator inhibitor-1 (PAI-1) and interleukin-6 (IL-6), etc.  TNF- α, PAI-1 and IL-
6 are all proinflammatory cytokines, although IL-6 can exert anti-inflammatory 
properties in addition1.  It has also been observed that leptin, resistin and 
TNF-α also impair insulin sensitivity and trigger atherogenesis1. These 
adipokines usually increase with adiposity and can have a detrimental role on 
an individual’s health. Adiponectin, however, unlike other adipokines 
produced by adipose tissue, possesses anti-atherogenic properties and is 
found to decrease with increased adiposity. 1,2 
 
Several studies provide evidence of improvements in adipokine profiles with 
weight loss3-6. However, it remains unclear, whether changes in circulating 
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adipokines investigated to date contribute significantly to the beneficial effects 
in health associated with weight loss7.  The extent of weight loss required to 
elicit such changes in adipokine levels remains unclear. In addition, the 
method by which the weight loss is achieved may also influence the adipokine 
response.  Varady and co-workers 8, suggest that a minimum weight loss of 
5% is required to have an effect on levels of key adipokines (adiponectin, 
leptin and resistin), however, this differs from other studies which report the 
need for a 10% weight loss for the modification in the levels of some 
adipokines (e.g. adiponectin) and that this varies with the degree of obesity9. 
 
Further studies are needed to clarify the relationship between changes in 
adipokine levels and the health benefits of weight loss, and whether specific 
dietary manipulations have differential effects on such changes. We 
hypothesised that the extent of weight loss rather than the macronutrient 
intake will determine the degree of change in adipokine levels. 
 
We aimed to investigate the effect of weight loss on adipokine levels in 
individuals undergoing a low carbohydrate/high protein (LCHP) compared to a 
very low calorie diet (LighterLife UK Ltd (LL)) diet. 
 
 
Methods 
The present analysis is an ancillary study to that previously presented by 
Rolland et al 10 where the methods were previously described. Here, the drop 
outs were not included in this analysis as the goal was to evaluate the effect 
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of diet on adipokine levels and not an intention-to-treat clinical trial.  In brief, 
patients referred to a Specialist Obesity Clinic were entered into a randomised 
controlled clinical trial (RCT) of differing dietary intervention in the 
management of obesity. Men and women older than 18 years of age and a 
BMI ≥ 35 kg/m 2 were included.  Patients with a history of hepatic or renal 
disease, cancer, with current pregnancy/lactating, on anti-depressants or anti-
obesity medication, or eating disorders were excluded. All patients who 
fulfilled these criteria were invited to take part in the study. This study included  
a three month screening period where patients were assigned to 600 calorie 
deficient diet (CDD) aiming to achieve a 5% percent weight loss. This was 
done to select patients who would not respond to a low fat, reduced energy 
approach and randomly assign them to a low carbohydrate/high protein 
(LCHP) or a very-low-calorie diet (VLCD)(LighterLife – LL) in a form of 
continuous method approach.  Those who lost > 5% of their body weight were 
maintained on this approach for an additional 3 months. If weight loss was > 
10% at this time, the CDD was continued for an additional 6 months. 
Completers data for this group were limited (n = 4) and, therefore, not 
included in this paper. 
 
Those patients who failed to achieve the weight loss targets were randomly 
allocated to either LCHP or LL, and continued on the assigned diet for an 
additional 9 months (Figure 1). Patients on CDD who achieved a 5% weight 
loss at screening but did not achieve the 10% weight loss 3 months post-
screening, were randomised to LL or LCHP but their data were omitted from 
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this analysis.  All patients provided written informed consent. The study was 
approved by the North of Scotland Research Ethics Service. 
 
<< INSERT FIGURE 1 HERE>> 
 
Dietary intervention 
Screening Period 
Using the Schofield and the Harris Benedict Equations, 600-kcalories were 
removed from the patients’ estimated daily energy intake. The amount of 
energy allowed was broken down into portions of different food groups 10. 
Portion sizes were explained to the patients and written information was also 
provided. Patients were reviewed at 2, 4, 8 and 12 weeks when they were 
weighed, their weight loss progress was discussed and, were provided with 
dietary advice.  
 
Randomisation and diet allocation 
Patients randomised to LCHP were restricted to ≤40 g of carbohydrate per 
day. The energy intake ranged from 800-1500kcal where an 800 kcal diet was 
composed of 20% carbohydrate, 40% protein and 40% fat. Patients were 
given a booklet with information about which foods to eat and which to avoid. 
Examples of recipes were also provided. The diet was supplemented with 
multivitamins and minerals (Forceval, Alliance Pharmaceuticals, Chippenham, 
UK).  
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LighterLife is a VLCD which is administered in the shape of soups, shakes 
and bars to replace conventional food and provide a daily average of 550 kcal 
(36% carbohydrate, 36% protein and 28% fat and at least 100% RDAs for all 
micronutrients). Patients on it were advised to remain adequately hydrated 
while on the diet. LL has two distinctive stages: weight loss and food 
reintroduction. During each stage, patients attend weekly single-sex group 
meetings of 7-12 people for behaviour change therapy based on cognitive 
behaviour therapy and transactional analysis methodology delivered by a 
trained LL advisor. Patients were required to remain on the weight loss phase 
for a minimum of 3 months after which they were given a choice to continue 
for up to another 6 months or assigned to the food reintroduction phase. On 
average, patients who completed the study remained on the diet for 6.9 
months (range: 4 - 9 months).  For the food reintroduction phase, solid foods 
were reintroduced over a 12 week period where patients were slowly weaned 
off food packs while still receiving advice and support.  
 
All patients came monthly to the trial centre to be weighed for the first 3 
months and then every alternate month post-screening, resulting in 6 visits in 
9 months. Additional support was provided via telephone and email. 
 
 
Data Collection 
Fat mass and fat free mass was estimated using bioelectrical impedance 
(Tanita BC-418 MA) (Tanita Corp., Arlington Heights, Illinois). Body 
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composition, and waist circumference were measured pre-screening, at 
screening, 3 and 9 months post-screening.  
 
Blood samples were obtained after an overnight fast pre-screening, at 
screening, 3 and 9 months post-screening to measure fasting plasma 
glucose, insulin, adipokines including leptin, resistin, adiponectin, PAI-1 
(active), IL-6, and TNF-α.  Serum samples for adipokines and insulin were 
measured in duplicate by using commercially available immunoassay kits 
from Millipore using the Lincoplex system (St.Charles, MO). The protocol for 
measurement of insulin and all the adipokines was carried out as described 
by the manufacturer. The sensitivities are described in Table 1. Intra-assay 
variations ranged from 1.4-7.9 % coefficient of variation. High density 
lipoprotein cholesterol (HDL), triacylglycerol and fasting glucose were 
analysed in the Department of Clinical Biochemistry at NHS Grampian. Insulin 
resistance using fasting glucose and insulin values was calculated using the 
Homeostasis Model of Assessment of Insulin Resistance (HOMA-IR) where 
HOMA-IR = [insulin][glucose]/22.5. 
 
<<INSERT TABLE 1 HERE>> 
 
Statistical methods 
All variables were assessed for normality using the Kolmogorov-Smirnov test. 
Any skewed data were log-transformed and subsequently assessed using 
parametric tests. For within group analysis, a paired t-test was used. For 
between-group analysis of changes, independent t-tests were used. Pearson 
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correlation was used to assess the relationship between changes in 
adipokines and changes in other continuous measurements. A Chi squared 
test was used to assess differences for dichotomous variables.  Statistical 
tests were carried out using SPSS 15.0 for Windows software program 
(SPSS, Chicago, IL). As this is an ancillary analysis to a previously published 
study10, the power for this analysis was carried out based on weight loss. A p-
value of < 0.05 (two-tailed) was considered statistically significant. Based on 
the mean change (31.0 kg) and standard deviation (16.4 kg) for weight loss 
observed at 9 months 10, 14 patients in each group resulted in a >99% power 
for weight change. 
 
Results 
Data are presented as means ± standard deviation, and changes are 
expressed as the mean difference change from baseline ± standard 
deviations. 
 
Baseline 
Baseline characteristics are listed in Table 2. A total of 31 (14 in LL: 17 in 
LCHP) patients completed the study.  There were significantly more men in 
the LL than the LCHP group (n = 5 and n = 1 respectively). Participants on LL 
also had significantly greater weight, BMI, waist circumference and fat free 
mass than the LCHP group.  
 
<<INSERT TABLE 2 HERE>> 
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Weight, BMI, FFM were also significantly greater in the LL than the LCHP 
group (Table 2). When investigating the whole group, significant associations 
were observed between adiponectin, HDL and PAI-1. PAI-1 also had 
significant associations with insulin and HOMA-IR. Leptin was significantly 
associated with percentage body fat and TNF- α, while IL-6 was inversely 
associated with HDL (Table 3). There were no significant gender differences 
for the adipokines with the exception of leptin, where levels were significantly 
greater in women than men (46.7 ± 15.5 vs 28.2 ± 14.6, p = 0.014). This, 
however, was no longer significant after adjusting for percentage body fat (p = 
0.089).  
 
<<INSERT TABLE 3 HERE>> 
 
Three month data 
At 3 months, percentage weight loss for LCHP was -2.9% ± 4.2 and for LL 
was -18.4% ± 5.4 (p<0.0001). Weight, waist circumference, percentage body 
fat, fat mass, leptin, PAI-1, fasting glucose, HOMA-IR, triacylglycerols had all 
improved significantly in the LL group (Table 4). However, HDL and fat free 
mass decreased significantly from baseline in the LL group (Table 4).  
 
A significant improvement from baseline to 3 months was observed for weight, 
percentage body fat, fat mass, insulin and HOMA-IR for the LCHP group 
(Table 4).  
 
<<INSERT TABLE 4 HERE>> 
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Nine month data 
At 9 months, percentage weight change for LCHP was -1.4% (1.0) and for LL 
was -23.8% ± 4.0 (p<0.0001). In the LL group, weight loss, waist 
circumference, percentage body fat, fat mass, fat free mass, leptin, PAI-1, 
fasting glucose, triacylglycerols were still significantly improved compared to 
baseline (Table 4). In addition, significant improvements in circulating levels of 
adiponectin, and HDL were observed but HOMA-IR was no longer significant 
(Table 4). Changes in adiponectin were inversely associated with changes in 
weight, BMI, fat mass, percentage body fat, waist circumference, IL-6 and 
TNF- α . Changes in leptin were associated with changes in weight, BMI, fat 
mass, waist circumference, fat free mass, and percentage body fat. Changes 
in leptin were inversely associated with HDL. Changes in TNF-α were 
associated with changes in IL-6, and inversely associated with changes in 
adiponectin. Changes in PAI-1 were associated with changes in fat mass 
(Table 5). 
 
<<INSERT TABLE 5 HERE>> 
 
There were no significant changes from baseline at 9 months for the LCHP 
group (Table 4). Changes in leptin, however, were inversely associated with 
changes in HDL (r = – 0.573, p = 0.032). 
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Overall, changes at 9 months for weight, waist circumference, fat mass, 
adiponectin, leptin, fasting glucose and HDL were significantly greater for LL 
than LCHP (Table 4). 
 
Discussion 
In the present study, there was a significant weight loss at 3 months for 
patients on both LL and LCHP. Significant weight loss at 9 months, however, 
was only maintained in the LL group. Changes in adiponectin and leptin were 
significantly greater for LL than LCHP which may be due to the greater weight 
loss and decrease in fat mass. Changes in TNF-α, IL-6, PAI-1 and resistin, 
however, did not differ significantly between the dietary groups at 9 months.  
 
 At baseline, we observed a trend for adiponectin to be inversely correlated 
with weight and BMI, but this did not reach significance, possibly due to the 
small sample size. Surprisingly, there was no significant inverse correlation 
between adiponectin and waist circumference which is unexpected, as other 
studies have demonstrated that waist circumference is a good correlate for 
adiponectemia 12,13.  Although the sample size was small, this may not be the 
reason for the lack of correlation of adiponectin to BMI and waist 
circumference.  Mean BMI for the participants in the study was greater than 
40 kg/m2.  There is evidence to suggest that the incidence of metabolic 
syndrome decreases beyond a BMI of 37.5 kg/m2 14.  
 
Interestingly, our findings supported the evidence presented by Plaisance et 
al 15, where baseline adiponectin levels were strongly correlated with mean 
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HDL cholesterol.  Association of moderately decreased risk of CVD with 
increased adiponectin is thought to be mediated in part by the effects of 
adiponectin on HDL, through parallel increases in both. However, how 
adiponectin affects HDL remains unknown 16. In the LL group, changes in 
adiponectin were significant at 9 months but not at 3 months.  Weight loss 
increased significantly from 3 to 9 months in this group which would suggest 
that a weight loss greater than 18.4% is required for statistically significant 
improvements in circulating adiponectin levels. Changes in adiponectin were 
inversely associated with fat mass, waist circumference, IL-6 and TNF-α at 9 
months suggesting an improvement in inflammatory status with weight loss 
and the associated increase in adiponectin. 
 
In the present study, leptin was significantly associated with percentage body 
fat at baseline, which is consistent with the previous findings 17. There was no 
significant correlation found between leptin and waist circumference in the 
present study at baseline.  This suggests that there may be a greater release 
of leptin from peripheral subcutaneous adipose tissue compared to visceral 
adipose tissue. Studies have shown that there are variations in leptin gene 
expression in adipose tissue depending on the site where it is deposited, 
where expression is greater in subcutaneous compared to visceral adipose 
tissue 18,19.  Alternatively, the lack of association between leptin and waist 
circumference may have been due to issues in the measurement of waist 
circumference in the grade III obese patients, a difficulty which is well 
recognised. Establishing the correct location and reading the tape in situ can 
be problematic. In addition, different protocols yield different results 20.  
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Leptin was significantly decreased at 3 and 9 months for the LL group. The 
changes in leptin were significantly associated with fat mass, percentage body 
fat, waist circumference. This is consistent with a number of studies in which 
leptin is shown to decrease in response to weight loss 21-24. There was also an 
association in leptin change with waist circumference change at 9 months 
reflecting an overall loss of fat mass. In addition, despite the minimal weight 
loss for the LCHP group, changes in leptin were inversely associated with 
HDL at 9 months. This may suggest that even a small reduction in weight 
results in a beneficial trend for improvements in leptin levels which are likely 
to improve cardiovascular risk. 
 
Levels of PAI-1 at baseline were associated with waist circumference, HOMA-
IR and insulin, suggesting that PAI-1 is involved in insulin resistance as 
previously reported 25.  Weight loss has been found to reduce the levels of 
PAI-1 26-28, indicating the influence of adipose tissue on the levels of this 
protein. Our study data are in support of this evidence where changes in PAI-
1 were associated with changes in fat mass for the LL group at 9 months.  
 
There was no evidence from the present study to support a strong link 
between resistin levels and weight. Of all the adipokines examined in this 
study, resistin appears to be the most controversial as the evidence appears 
to be equivocal and inconclusive 29-31.  Further human studies are required to 
confirm whether there is a relationship between resistin and obesity, including 
insulin resistance and type 2 diabetes mellitus. 
15 
 
 
Similarly, despite the fact that IL-6 has been found to be increased in obesity 
32,33  and reduced in response to weight loss 34, no significant differences at 
baseline or in response to diet were observed here. Subcutaneous adipose 
tissue is thought to release ~ 30% of systemic IL-6, and visceral adipose 
tissue is thought to release even more. The lack of change, however, may be 
explained by the fact that only about 10% of total IL-6 produced by fat cells 35. 
  
In addition, mean levels of TNF-α, did not significantly correlate with neither 
weight, waist circumference nor percentage body fat at baseline. These 
results were unexpected, as it is widely reported that TNF-α is linked to 
obesity 36. Also, TNF-α did not show any significant decreases in response to 
weight loss or diet. However, in the study by Arvidsson et al 37, circulating 
levels of TNF-α did not show a significant difference after a mean weight loss 
of 7.5 % at 10 weeks. These authors concluded that adipose tissue only has a 
minor effect on the regulation of circulating TNF-α levels. Thus, TNF-α seems 
to be produced and act locally in human fat tissue 38, and there is no in situ 
release from adipose tissue into the blood 35. A number of studies have 
observed no changes in IL-6, or TNF-α after significant reductions in weight 
(5–9 kg) in dietary and exercise interventions 39,40.  
 
It was, however, interesting to observe that changes in IL-6 and TNF- α were 
significantly correlated at 9 months in the LL group. This could be explained 
by the relation between IL-6 and TNF- α where IL-6 exerts pro-inflammatory 
activity itself and by increasing TNF- α 1. This would suggest that despite 
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weight loss not resulting in significant improvements in circulating levels of IL-
6 and TNF- α, there appears to be an underlying clinically significant response 
where the reduction in weight results in a decrease in inflammation. 
There is evidence that weight loss achieved using a VLCD results in similar 
changes in adipokine levels observed in response to bariatric surgery. 
Mitterberger et al 41 compared a group of patients for whom weight loss was 
achieved by dietary caloric restriction only to a group where caloric restriction 
was induced by bariatric surgery (3 gastric bypasses and 8 gastric bands).  
They reported that despite the fact that only 26 ± 7% weight loss was 
achieved in the dietary caloric restriction as compared to 43 ± 10% in the 
bariatric surgery group, changes in adipokines were not significantly different 
between the two groups. This may suggest an important role for the use of a 
weight loss approach such as the VLCD “instead of” bariatric surgery which is 
highly invasive, expensive and can lead to long-term vitamin and mineral 
deficiencies 42. 
 
Although it remains unclear as to whether adipokines investigated to date are 
responsible for the beneficial effects in health associated with weight loss, it is 
clear from this study and several others, that there are important associations 
between weight loss, certain adipokines such as adiponectin, and leptin levels 
and cardiovascular disease risk. In addition, the extent of weight loss required 
to elicit the benefits as well as the effects of the method by which weight loss 
is obtained remains unknown. It can, however, be argued that there does 
seem to be a minimal weight loss required which was not achieved here in the 
LCHP and a maximal weight loss beyond which further improvements in 
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circulating  adipokine levels are no longer observed as demonstrated in the 
study by Mitterberg et al 41. Further research would include determining if 
there is a ceiling effect for adipokine change in response to weight loss. This 
would involve directly comparing adipokine changes in response to weight 
loss achieved by using a VLCD as compared to weight loss achieved using 
surgical approaches. 
 
 
There were several limitations associated with the present study. There were 
significantly more men in LL than LCHP, however, this may not have been too 
limiting as there were no significant gender effects on adipokine when all 
patients were combined at baseline except for leptin, but it may have resulted 
in the significant differences between the two groups at baseline for weight, 
waist circumference and fat free mass. In addition, although the sample size 
provided a >99 % power for weight loss, the sample sizes may have been too 
small to observe associations and changes in adipokines, which would have 
been expected based on the literature. 
 
Moreover, the use of multiplex assay has been criticised in the scientific 
literature 43. The multiplexed bead immunoassay (allows the simultaneously 
detection of adipokines in small blood samples which may be particularly 
useful when samples are difficult to obtain). The use of this approach has 
been validated and found to be useful for leptin, adiponectin and insulin in the 
evaluation of changes in obesity markers following weight reduction43.  The 
relationship between multiplexed bead immunoassay when compared to radio 
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immunoassay or enzyme-linked immunoassay (ELISA) for other adipokines 
such as resistin, IL-6 and TNF-α, however, were reported to be quite weak. 
These differences could be explained by differences in anti-body pairs and 
sample diluents as well as being affected by the low concentrations of these 
adipokines. In addition, assay sensitivity remains an issue when compared to 
ultra-sensitive ELISA methods 43.  However, the ability of multi-plexed assays 
to detect adipokines of a broader dynamic range than ELISAs as well as its 
greater cost-effectiveness, time efficient, requirement of smaller sample 
volume, and the removal of inter-assay variability suggest that this approach 
is still to be considered a powerful tool, albeit with the above limitations. 
 
Conclusion 
It would appear that the significant weight loss of 23.8% observed on LL 
resulted in significant improvements in circulating levels of leptin, PAI-1 and 
adiponectin. Changes in these adipokines possibly resulted in improvements 
in fasting glucose, triacylglycerols and HDL. This is most likely due to the 
overall weight loss achieved rather than macronutrient intake. Further 
research examining the adipokine response to weight loss using a very low 
calorie diet in comparison to surgical interventions would be beneficial to 
determine if the adipokine response to weight loss has a ceiling effect. 
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Table 1: Assay sensitivities for the measured adipokines. 
Adipokine Sensitivity 
(pg/ml) 
Adiponectin 145.4 
Insulin 50.9 
Interleukin-6 1.6 
Leptin 85.4 
Plasminogen activator inhibitor-1 (active) 
Resistin  
1.3 
4.5 
Tumour necrosis factor -α 0.14 
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Table 2: Baseline characteristics of the two dietary interventions.  
Variable LL (n = 14)  LCHP (n = 17) P 
Age (years) 41.9 ± 6.5 45.8 ± 13.8 0.314 
Gender 
           male 
          female 
 
5 (36) 
9 (64) 
 
1 (6) 
16 (94) 
 
0.036 
# of smokers 0 (0) 1 (6) 0.356 
Weight (Kg) 129.5 ± 23.9 110.1 ± 10.6 0.012 
BMI (Kg/m2) 46.7 ± 9.0 40.6 ± 3.7 0.031 
Waist circumference (cm) 127.5 ± 17.8 123.8 ± 10.6 0.031 
Fat mass (Kg) 61.7 ± 18.8 52.6 ± 7.6 0.110 
Fat free mass (Kg) 67.8 ± 14.3 57.4 ± 8.1 0.025 
Percentage body fat (%) 47.2 ± 8.4 47.8 ± 4.9 0.797 
Adiponectin (ng/ml) 20.3 ± 12.5 24.7 ± 14.4 0.384 
IL-6 (pg/ml) 4.4 ± 2.9 2.9 ± 2.4 0.119 
Leptin (ng/ml) 42.3 ± 20.3 43.5 ± 13.8 0.860 
PAI-1 (active) (ng/ml) 52.5 ± 29.7 59.4 ± 54.0 0.926 
Resistin (ng/ml) 21.1 ± 7.2 21.4 ± 18.2 0.164 
TNFα (pg/ml) 4.3 ± 2.7 5.1 ± 2.0 0.549 
Insulin (µUI/ml) 12.3 ± 8.2 14.6 ± 6.6 0.212 
Fasting glucose (mmol/L) 5.3 ± 0.8 5.3 ± 0.6 0.912 
HOMA-IR 3.1 ± 2.6 3.5 ± 1.8 0.619 
HDL (mmol/L) 1.3 ± 0.2 1.4 ± 0.3 0.190 
Triacylglycerol (mmol/L) 1.2 ± 0.7 1.6 ± 1.2 0.178 
Values are means ± standard deviation; (percentages).  
* Baseline differences were significantly different (p<0.05) between the two groups. 
BMI, body mass index; HDL – high density lipoprotein cholesterol ; HOMA-IR – Homeostatic 
Model Assessmen-Insulin resistance; IL-6, interleukin-6; LCHP, low carbohydrate/high 
protein; LL, Lighterlife; PAI-1, plasminogen activator inhibitor – 1; TNFα – tumor necrosis 
factor alpha. 
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Table 3: Baseline correlations for all study participants. 
 
 Adipo IL-6 Leptin PAI-1 Resistin TNF- α Insulin 
Weight  -0.044 0.220 0.019 0.059 0.241 -0.079 0.090 
BMI  -0.107 0.353 0.333 0.127 0.315 0.167 0.045 
WC  0.033 0.143 -0.036 0.144 0.211 -0.124 0.379* 
FM -0.033 0.320 0.309 0.150 0.326 0.124 0.061 
FFM -0.069 -0.023 -0.333 -0.079 0.014 -0.277 0.074 
% BF 0.084 0.256 0.478** 0.149 0.285 0.284 -0.014 
Adipo - -0.128 0.086 -0.316 0.103 0.128 -0.289 
IL-6  -0.128 - 0.220 0.109 0.056 0.252 0.231 
Leptin  0.086 0.220 - 0.061 0.000 0.391* 0.257 
PAI-1  -0.316 0.109 0.061 - -0.022 -0.101 0.386* 
Resistin  0.103 0.056 0.000 -0.022 - -0.169 -0.099 
TNF-α  0.128 0.252 0.391* -0.101 -0.169 - 0.165 
Insulin  -0.298 0.231 0.257 0.386* -0.099 0.165 - 
FG -0.294 0.055 -0.119 0.223 0.123 0.287 0.331 
HOMA -0.344 0.141 0.207 0.399* -0.049 0.212 0.979** 
HDL 0.455* -0.374* 0.053 -0.263 -0.062 0.154 -0.357 
TAG 0.010 -0.188 -0.272 0.249 0.058 0.052 0.023 
 
%BF, percent body fat; Adipo, adiponectin; BMI, body mass index; FG, fasting glucose; FM, 
fat mass; FFM, fat free mass; HDL – high density lipoprotein cholesterol ; HOMA – 
Homeostatic Model Assessment; IL-6, interleukin -6; PAI-1, plasminogen activator inhibitor – 
1;TAG, triacylglycerol; TNFα – tumor necrosis factor alpha; WC – waist circumference. 
 
*P <0.05 
** P <0.01 
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Table 4: Changes in variables between baseline and 3 and 9 months (completers only) 
Variable Baseline 3 months 9 months Change at 9 months P (change between 
both studies at 9 
months) 
 
Weight (Kg) 
LL (n = 14) 
       LCHP (n=17) 
 
 
129.5 ± 23.9 
110.1 ± 10.6 
 
 
105.5 ± 20.1* 
107.1 ± 13.7* 
 
 
97.2 ± 20.8* 
108.7 ± 13.2 
 
 
-32.3 ± 22.7 
-1.3 ± 4.7 
 
 
<0.0001 
 
BMI (Kg/m2) 
   LL 
              LCHP 
 
 
46.7 ± 9.0 
40.6  ± 3.6 
 
 
38.1  ± 7.6 
39.5  ± 4.3 
 
 
34.4  ± 9.2* 
40.1  ± 4.1 
 
 
-12.3  ± 10.0* 
-0.5  ± 1.8 
 
 
0.001 
 
Waist 
circumference 
(cm)         
LL 
     LCHP 
 
 
 
 
127.5 ± 17.8 
123.8 ± 10.6 
 
 
 
 
112.3 ± 17.5* 
121 ± 9.9 
 
 
 
 
102.5 ± 10.4*† 
120.1 ± 10.1 
 
 
 
 
-25.0 ± 17.7 
-3.7 ± 8.0 
 
 
 
 
0.001 
 
Fat mass (Kg) 
LL 
     LCHP 
 
 
61.7 ± 18.8 
52.6 ± 7.6 
 
 
43.2 ± 14.7* 
50.3 ± 9.2* 
 
 
34.4 ± 18.3*† 
52.1 ± 10.8 
 
 
-27.3 ± 19.0 
-0.5 ± 4.9 
 
 
<0.0001 
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Fat free mass 
(Kg) 
LL 
     LCHP 
 
 
 
67.8 ± 14.3 
57.4 ± 8.1 
 
 
 
62.4 ± 12.7* 
56.8 ± 9.2 
 
 
 
62.7 ± 13.5* 
56.6 ± 8.4 
 
 
 
-5.1 ± 5.3 
- 0.8 ± 2.8 
 
 
 
0.638 
 
Percentage body 
fat (%) 
LL 
             LCHP 
 
 
 
47.2 ± 8.4 
47.8 ± 4.9 
 
 
 
40.5 ± 8.7* 
46.7 ± 5.3* 
 
 
 
34.3 ± 12.9*† 
47.7 ± 6.0 
 
 
 
-12.9 ± 9.4 
-0.1 ± 2.6 
 
 
 
<0.0001 
 
Adiponectin 
(ng/ml) 
LL 
     LCHP 
 
 
 
20.3 ± 12.5 
24.7 ± 14.4 
 
 
 
22.4 ± 7.8 
23.9 ± 13.2 
 
 
 
36.1 ± 11.1*† 
23.9 ± 13.2 
 
 
 
15.8 ± 17.1 
-0.8 ± 6.2 
 
 
 
0.003 
 
IL-6 (pg/ml) 
LL 
     LCHP 
 
 
4.4 ± 2.9 
2.9 ± 2.4 
 
 
4.5 ± 5.3 
3.1 ± 3.8 
 
 
4.4 ± 5.4 
2.5 ± 1.7 
 
 
0.1 ± 4.4 
-0.4 ± 2.5 
 
 
0.716 
 
Leptin (ng/ml) 
LL 
     LCHP 
 
 
42.3 ± 20.3 
43.5 ± 13.8 
 
 
26.1 ± 21.8* 
41.1 ± 17.1 
 
 
24.7 ± 21.1* 
40.5 ± 14.7 
 
 
-17.6 ± 24.3 
-3.0 ± 9.2 
 
 
0.049 
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PAI-1 (active) 
(ng/ml) 
LL 
    LCHP 
 
 
52.5 ± 29.7 
59.4 ± 54.0 
 
 
20.2 ± 11.1* 
50.6 ± 43.3 
 
 
20.5 ± 19.3* 
49.0 ± 44.9 
 
 
-32.0 ± 34.4 
-10.5 ± 56.2 
 
 
0.727 
 
Resistin (ng/ml) 
  LL 
     LCHP 
 
 
21.1 ± 7.2 
21.4 ± 18.2 
 
 
17.4 ± 7.0 
16.4 ± 11.0 
 
 
16.7 ± 7.6 
16.0 ± 7.5 
 
 
-4.4 ± 9.5 
-5.5 ± 15.8 
 
 
0.720 
 
TNFα (pg/ml) 
  LL 
    LCHP 
 
 
4.3 ± 2.7 
5.1 ± 2.0 
 
 
4.1 ± 2.6 
5.1 ± 2.7 
 
 
4.5 ± 2.9 
5.2 ± 2.0 
 
 
0.3 ± 2.8 
0.2 ± 1.5 
 
 
0.928 
 
Insulin (µUI/ml) 
LL 
             LCHP 
 
 
12.3 ± 8.2 
14.6 ± 6.6 
 
 
10.6 ± 12.7 
12.1 ± 6.5* 
 
 
10.9 ± 7.4 
12.2 ± 7.3 
 
 
-3.7 ± 7.4 
- 4.0 ± 11.1 
 
 
0.902 
 
Fasting glucose 
(mmol/L) 
LL 
             LCHP 
 
 
 
5.3 ± 0.8 
5.3 ± 0.6 
 
 
 
4.6 ± 0.5* 
5.4 ± 0.6 
 
 
 
4.7 ± 0.3* 
5.2 ± 0.5 
 
 
 
-0.7 ± 0.9 
-0.1 ± 0.5 
 
 
 
0.034 
 
HOMA-IR 
LL 
 
 
3.1 ± 2.6 
 
 
2.1 ± 2.5* 
 
 
2.2 ± 1.5 
 
 
-1.6 ± 2.4 
 
 
0.832 
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             LCHP 3.5 ± 1.8 2.9 ± 1.6* 2.8 ± 1.8 -1.1 ± 2.7 
 
HDL (mmol/L) 
LL 
             LCHP 
 
 
1.3 ± 0.2 
1.4 ± 0.3 
 
 
1.2 ± 0.1* 
1.4 ± 0.3 
 
 
1.5 ± 0.2*† 
1.4 ± 0.4 
 
 
0.2 ± 0.2 
0.0 ± 0.2 
 
 
0.018 
 
Triacylglycerol 
(mmol/L) 
LL 
             LCHP 
 
 
 
1.2 ± 0.7 
1.6 ± 1.2 
 
 
 
0.9 ± 0.2* 
1.5 ± 0.9 
 
 
 
0.7 ± 0.2* 
1.4 ± 0.9 
 
 
 
-0.4 ± 0.8 
-0.2 ± 0.7 
 
 
 
0.070 
 
Values are means ± standard deviation. 
* Indicates a significant difference (p<0.05) from baseline. 
† Indicates a significant difference (p<0.05) from 3 months. 
BMI, body mass index; IL-6, interleukin -6;  PAI-1, plasminogen activator inhibitor – 1; TNFα – tumor necrosis factor alpha; HOMA-
IR – Homeostatic model assessment-insulin resistance; HDL – high density lipoprotein; LDL – low density lipoprotein; TC – total 
cholesterol. 
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Table 5: Correlations for changes from baseline to 9 months for the 
LighterLife group. 
 
 Adipo IL-6 Leptin PAI-1 Resistin TNF- α Insulin 
Weight  -0.560* 0.213 0.743** 0.505 -0.072 0.158 0.224 
BMI  -0.612** 0.258 0.730* 0.462 -0.147 0.265 0.126 
WC  -0.578* 0.217 0.720** 0.488 -0.064 0.158 0.105 
FM -0.637* 0.282 0.695** 0.558* -0.064 0.237 0.204 
FFM -0.119 -0.117 0.694** 0.165 -0.081 -0.189 0.296 
% BF -0.681** 0.317 0.635* 0.531 -0.007 0.241 0.209 
Adipo - -0.868** -0.392 -0.407 -0.076 -0.740** 0.317 
IL-6  -0.868** - 0.209 0.186 0.220 0.779** -0.460 
Leptin  -0.392 0.209 - 0.474 -0.133 0.003 0.596 
PAI-1  -0.407 0.186 0.474 - -0.330 -0.193 0.544 
Resistin  -0.076 0.220 -0.133 -0.330 - 0.141 -0.049 
TNF-α  -0.740** 0.779** 0.003 -0.193 0.141 - -0.466 
Insulin  0.317 -0.460 0.596 0.544 -0.049 -0.466 - 
FG -0.427 0.177 0.439 0.238 -0.114 0.294 -0.115 
HOMA 0.144 -0.337 0.708 0.652 -0.73 -0.349 0.917** 
HDL -0.506 -0.171 -0.573* -0.508 -0.332 0.046 -0.412 
TAG 0.531 0.306 0.336 0.437 0.105 0.130 0.417 
 
%BF, percent body fat; Adipo, adiponectin; BMI, body mass index; FG, fasting glucose; FM, 
fat mass; FFM, fat free mass; HDL – high density lipoprotein cholesterol ; HOMA – 
Homeostatic Model Assessment; IL-6, interleukin -6; PAI-1, plasminogen activator inhibitor – 
1;TAG, triacylglycerol; TNFα – tumor necrosis factor alpha; WC – waist circumference. 
 
*P <0.05 
** P <0.01 
 
